Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Br J Haematol

Retrieve available abstracts of 464 articles:
HTML format

Single Articles

    June 2022
  1. BRIVIO E, Cossio A, Borra D, Silvestri D, et al
    Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort.
    Br J Haematol. 2022;197:602-608.
    PubMed     Abstract available

  2. WALEWSKA R, Parry-Jones N, Eyre TA, Follows G, et al
    Guideline for the treatment of chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:544-557.

  3. MOIA R, Gaidano G
    Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:513-514.

  4. WANG QQ, Wang HF, Zhao JZ, Naranmandura H, et al
    Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e58-e60.

  5. MERLI P
    Treating second-relapsed/refractory first-relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
    Br J Haematol. 2022;197:651-652.
    PubMed     Abstract available

  6. WANG M, Lin H, Chu X, Wang Z, et al
    Identification of a recurrent fusion NUP98-RARG in acute myeloid leukaemia resembling acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e73-e78.

  7. LYNGGAARD LS, Vaitkeviciene G, Langenskiold C, Lehmann AK, et al
    Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:745-754.
    PubMed     Abstract available

  8. TARIQ H, Barnea Slonim L, Coty Fattal Z, Alikhan MB, et al
    Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
    Br J Haematol. 2022;197:736-744.
    PubMed     Abstract available

  9. MORI A, Onozawa M, Tsukamoto S, Ishio T, et al
    Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
    Br J Haematol. 2022;197:691-696.
    PubMed     Abstract available

  10. WHITE T, Kaspers G, Abrahamsson J, Arad-Cohen N, et al
    Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO-DB SHIP consortium.
    Br J Haematol. 2022;197:755-765.
    PubMed     Abstract available

    May 2022
  11. JOBSON D, McCormack CJ, Mar V, Tam C, et al
    Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study.
    Br J Haematol. 2022;197:320-325.
    PubMed     Abstract available

  12. TAYLOR T, Byrne J, Errico G, Clark D, et al
    Very late extramedullary relapse of acute myeloid leukaemia as prostatic myeloid sarcoma occurring 24 years post-allograft.
    Br J Haematol. 2022;197:243.

  13. OLIVEIRA AF, Tansini A, Toledo T, Balceiro R, et al

    Br J Haematol. 2022;197:339-348.
    PubMed     Abstract available

  14. UJJANI C, Shadman M, Lynch RC, Tu B, et al
    The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:306-309.
    PubMed     Abstract available

  15. CARTWRIGHT A, Scott S, Francis S, Whitby L, et al
    Assessing the impact of the 2017 European LeukemiaNet recommendations on FLT3 allelic ratio calculation and reporting in acute myeloid leukaemia.
    Br J Haematol. 2022;197:e35-e37.

  16. PETERSEN MA, Rosenberg CA, Brondum RF, Aggerholm A, et al
    Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups.
    Br J Haematol. 2022;197:452-466.
    PubMed     Abstract available

  17. WEI H, Zhou C, Liu B, Lin D, et al
    The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
    Br J Haematol. 2022;197:442-451.
    PubMed     Abstract available

  18. LEW TE, Anderson MA
    Health-related quality of life for patients with chronic lymphocytic leukaemia - A critical outcome measure in the era of highly effective therapies.
    Br J Haematol. 2022;197:394-396.

  19. OERLEMANS S, Efficace F, Kieffer JM, Kyriakou C, et al
    International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:431-441.
    PubMed     Abstract available

  20. JACOBY E, Bielorai B, Hutt D, Itzhaki O, et al
    Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:475-481.
    PubMed     Abstract available

  21. ALTER BP, Giri N, McReynolds LJ, Altintas B, et al
    Fanconi anaemia: A syndrome with distinct subgroups.
    Br J Haematol. 2022;197:467-474.
    PubMed     Abstract available

  22. YU Q, Yu D, Chen X
    Cup-shaped nuclei in acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:389.

    April 2022
  23. SUN C
    COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion.
    Br J Haematol. 2022;197:11-12.

  24. SHEN Y, Freeman JA, Holland J, Solterbeck A, et al
    COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
    Br J Haematol. 2022;197:41-51.
    PubMed     Abstract available

  25. CLAUDIANI S, Apperley JF, Parker EL, Marchesin F, et al
    Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
    Br J Haematol. 2022;197:e1-e4.

  26. ON S, Rath CG, Lan M, Wu B, et al
    Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
    Br J Haematol. 2022;197:63-70.
    PubMed     Abstract available

  27. GADI D, Griffith A, Wang Z, Tyekucheva S, et al
    Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:207-211.
    PubMed     Abstract available

  28. RECKZEH K, Estruch M, Ali M, Sogaard Helbo A, et al
    TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event.
    Br J Haematol. 2022;197:201-206.

    BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
    Br J Haematol. 2022;197:9-10.

  30. DOMINY KM, Claudiani S, O'Hare M, Szydlo R, et al
    Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
    Br J Haematol. 2022;197:52-62.
    PubMed     Abstract available

  31. VERBEEK MWC, Buracchi C, Laqua A, Nierkens S, et al
    Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Br J Haematol. 2022;197:76-81.
    PubMed     Abstract available

  32. HILLS RK
    Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?
    Br J Haematol. 2022;197:e26-e27.

  33. YEUNG DTO, Osborn MP, White DL
    B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
    Br J Haematol. 2022;197:13-27.
    PubMed     Abstract available

  34. TONG WH
    Does anticoagulation prophylaxis reduce the rate of venous thromboembolism in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy?
    Br J Haematol. 2022;197:e24-e25.

  35. JENSEN K, Oskarsson T, Lahteenmaki P, Flaegstad T, et al
    Doing less, accomplishing more for childhood ALL: response.
    Br J Haematol. 2022;197:120.

    March 2022
  36. CULL G, Burger JA, Opat S, Gottlieb D, et al
    Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
    Br J Haematol. 2022;196:1209-1218.
    PubMed     Abstract available

  37. MORIYA K, Imamura T, Katayama S, Kaino A, et al
    The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Munster (BFM)95-based protocol.
    Br J Haematol. 2022;196:1257-1261.
    PubMed     Abstract available

  38. MAAS CCHM, van Klaveren D, Ector GICG, Posthuma EFM, et al
    The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.
    Br J Haematol. 2022;196:1219-1224.
    PubMed     Abstract available

  39. BARZILAI-BIRENBOIM S, Elitzur S, Nirel R, Ehrenberg M, et al
    Elevated intraocular pressure in children with acute lymphoblastic leukaemia: A prospective study.
    Br J Haematol. 2022;196:1248-1256.
    PubMed     Abstract available

  40. DILLON R, Hills RK, Burnett AK, Russell NH, et al
    Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.
    Br J Haematol. 2022;196:e50-e52.

  41. WALDRON C, O'Brien D, Brophy S, Perera K, et al
    Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning.
    Br J Haematol. 2022;196:e47-e49.

  42. EGNELL C, Heyman M, Jonsson OG, Raja RA, et al
    Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:1239-1247.
    PubMed     Abstract available

  43. GALLIPOLI P, Clark RE, Byrne J, Apperley JF, et al
    The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
    Br J Haematol. 2022;196:e55-e57.

  44. COATS T, Bean D, Basset A, Sirkis T, et al
    A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
    Br J Haematol. 2022;196:1337-1343.
    PubMed     Abstract available

  45. SALHOTRA A, Tsai NC, Zhang J, Ngo D, et al
    Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2022;196:e71-e74.

  46. RUSSELL N, Hills R, Kjeldsen L, Dennis M, et al
    Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
    Br J Haematol. 2022;196:1344-1347.
    PubMed     Abstract available

  47. MCCLURE BJ, Pal M, Heatley SL, Rehn J, et al
    Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features.
    Br J Haematol. 2022;196:1407-1411.

  48. LINCH DC, Hills RK, Burnett AK, Russell N, et al
    Therapy for isocitrate dehydrogenase 2 (IDH2)(R172) -mutant acute myeloid leukaemia.
    Br J Haematol. 2022;196:1348-1352.
    PubMed     Abstract available

  49. BENDE RJ, Janssen J, van Noesel CJM
    Higher-order of chronic lymphocytic leukaemia (CLL) classification: shared antigenic specificities of stereotyped B-cell receptor subsets as defined by the European Research Initiative on CLL consortium.
    Br J Haematol. 2022;196:e60-e63.

  50. TAWANA K, Brown AL, Churpek JE
    Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges.
    Br J Haematol. 2022;196:1293-1310.
    PubMed     Abstract available

    February 2022
    Is COVID-19 less severe in CML patients than in those with other haematological cancers?
    Br J Haematol. 2022;196:471-472.

  52. BRECCIA M, Abruzzese E, Accurso V, Attolico I, et al
    COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
    Br J Haematol. 2022;196:559-565.
    PubMed     Abstract available

  53. SCHENKER C, Hirzel C, Walti LN, Zeerleder SS, et al
    Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.
    Br J Haematol. 2022;196:e27-e29.

  54. BIONDI A, Conter V, Chandy M, Ewald P, et al
    Precursor B-cell acute lymphoblastic leukaemia-a global view.
    Br J Haematol. 2022;196:530-547.
    PubMed     Abstract available

  55. SALEK C, Folber F, Fronkova E, Pecherkova P, et al
    Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.
    Br J Haematol. 2022;196:706-710.
    PubMed     Abstract available

  56. DOWNES CEJ, Rehn J, Heatley SL, Yeung D, et al
    Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:700-705.
    PubMed     Abstract available

  57. SCHWAB CJ, Murdy D, Butler E, Enshaei A, et al
    Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.
    Br J Haematol. 2022;196:753-763.
    PubMed     Abstract available

  58. TANDON S, Visser R, Astwood E, Payne J, et al
    Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature.
    Br J Haematol. 2022;196:e34-e39.

  59. KRIEG S, Seeger H, Hofmann P, Del Prete C, et al
    Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia.
    Br J Haematol. 2022;196:781-784.

  60. VOJDEMAN FJ, Helby J, Pedersen LB, Brieghel C, et al
    Chronic lymphocytic leukaemia clones are detectable decades before diagnosis.
    Br J Haematol. 2022;196:784-787.

  61. HUANG W, Sundquist K, Sundquist J, Ji J, et al
    Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
    Br J Haematol. 2022;196:690-699.
    PubMed     Abstract available

  62. RIBERA J, Granada I, Morgades M, Gonzalez T, et al
    Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
    Br J Haematol. 2022;196:670-675.
    PubMed     Abstract available

  63. BOOTH S, Curley HM, Varnai C, Arnold R, et al
    Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
    Br J Haematol. 2022;196:892-901.
    PubMed     Abstract available

  64. ALLAN JN, Shanafelt T, Wiestner A, Moreno C, et al
    Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    Br J Haematol. 2022;196:947-953.
    PubMed     Abstract available

  65. AHMED HMM, Nimmagadda SC, Al-Matary YS, Fiori M, et al
    Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells.
    Br J Haematol. 2022;196:995-1006.
    PubMed     Abstract available

  66. SHEN Z, Zhou M, Zhang J, Chen S, et al
    Microgranular variant of acute promyelocytic leukaemia with an unusual T/myeloid immunophenotype resembling that of mixed-phenotype acute leukaemia.
    Br J Haematol. 2022;196:801.

  67. ABDEL RAHMAN ZH, Parrondo RD, Heckman MG, Wieczorek M, et al
    Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:963-968.
    PubMed     Abstract available

  68. EYRE TA, Riches JC, Patten PEM, Walewska R, et al
    Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper.
    Br J Haematol. 2022;196:864-870.

    January 2022
  69. TOMOWIAK C, Leblond V, Laribi K, Baron M, et al
    Response to vaccination against SARS-CoV-2 in 168 patients with Waldenstrom macroglobulinemia: a French Innovative Leukemia Organization (FILO) study.
    Br J Haematol. 2022 Jan 14. doi: 10.1111/bjh.18055.

  70. NAVILLE AS, Lazaro E, Boutin J, Prot-Leurent C, et al
    Acquired glucose 6-phosphate dehydrogenase (G6PD) deficiency in a patient with Chronic Myelomonocytic Leukemia.
    Br J Haematol. 2022 Jan 6. doi: 10.1111/bjh.18037.

  71. SAULTIER P, Ninove L, Szepetowski S, Veneziano M, et al
    Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.
    Br J Haematol. 2022;196:e1-e3.

  72. MARCHESI F, Pimpinelli F, Sperandio E, Papa E, et al
    The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Br J Haematol. 2022;196:362-367.

  73. GASTINNE T, Le Bourgeois A, Coste-Burel M, Guillaume T, et al
    Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Br J Haematol. 2022;196:360-362.

  74. SEVIAR D, Nyunt K, Sayer C, Wright D, et al
    Romboutsia-induced bone marrow necrosis at presentation of acute myeloid leukaemia.
    Br J Haematol. 2022;196:262.

  75. YAO H, Huo L, Ping N, Liu H, et al
    Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia.
    Br J Haematol. 2022;196:441-444.

  76. KIM DDH, Kim TS, Atenafu EG, Novitzky Basso I, et al
    BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
    Br J Haematol. 2022;196:136-145.
    PubMed     Abstract available

  77. LOKE J, Metzner M, Boucher R, Jackson A, et al
    Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
    Br J Haematol. 2022;196:368-373.
    PubMed     Abstract available

  78. PODVIN B, Goursaud L, Roynard P, Nibourel O, et al
    Chronic myeloid leukaemia presenting with monocytosis.
    Br J Haematol. 2022;196:8.

  79. NAKAJIMA R, Matsuo T, Sumiyoshi R, Saito S, et al
    Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib.
    Br J Haematol. 2022;196:e9-e11.

  80. KAYSER S, Levis MJ
    Updates on targeted therapies for acute myeloid leukaemia.
    Br J Haematol. 2022;196:316-328.
    PubMed     Abstract available

  81. MIKHAILOVA E, Roumiantseva J, Illarionova O, Lagoyko S, et al
    Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
    Br J Haematol. 2022;196:e6-e9.

  82. SHANMUGANATHAN N, Branford S
    Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing.
    Br J Haematol. 2022;196:19-30.
    PubMed     Abstract available

    December 2021
  83. FOX TA, Kirkwood AA, Enfield L, O'Reilly M, et al
    Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
    Br J Haematol. 2021;195:706-709.

  84. KIM HS, Lee JW, Kang D, Yu H, et al
    Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Br J Haematol. 2021;195:748-756.
    PubMed     Abstract available

  85. MINGUELA A, Salido EJ, Soto-Ramirez MF, Olga MA, et al
    Low-affinity immunoglobulin gamma Fc region receptor III-B (FcgammaRIIIB, CD16B) deficiency in patients with blood and immune system disorders.
    Br J Haematol. 2021;195:743-747.
    PubMed     Abstract available

  86. SILLA L, Valim V, Pezzi A, da Silva M, et al
    Adoptive immunotherapy with double-bright (CD56(bright) /CD16(bright) ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study.
    Br J Haematol. 2021;195:710-721.
    PubMed     Abstract available

  87. TANG FF, Lu SY, Zhao XS, Qin YZ, et al
    PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort stud
    Br J Haematol. 2021;195:722-730.
    PubMed     Abstract available

    November 2021
  88. FOX CP, Ahearne MJ, Pettengell R, Dearden C, et al
    Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
    Br J Haematol. 2021 Nov 22. doi: 10.1111/bjh.17951.

  89. BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
    Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Br J Haematol. 2021;195:523-531.
    PubMed     Abstract available

  90. SHIMONI A, Robin M, Iacobelli S, Beelen D, et al
    Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    Br J Haematol. 2021;195:417-428.
    PubMed     Abstract available

  91. HWANG J, Singh N, Braniecki M, Gok Yavuz B, et al
    Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.
    Br J Haematol. 2021;195:e138-e141.

  92. SMYTH L, Blunt DN, Cheung MC
    Statins in mature B-cell lymphomas and leukaemias.
    Br J Haematol. 2021;195:490-492.

  93. SOLANO DE LA ASUNCION C, Terol MJ, Saus A, Olea B, et al
    Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
    Br J Haematol. 2021;195:637-641.

  94. BEGNA KH, Kittur J, Yui J, Gangat N, et al
    De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases.
    Br J Haematol. 2021;195:413-416.
    PubMed     Abstract available

  95. ZHONG ZQ, Zhuang HF, Wu SL, Zhang H, et al
    Pseudo-Chediak-Higashi inclusions in relapsed acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:300.

  96. SKOU AS, Juul-Dam KL, Ommen HB, Hasle H, et al
    Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
    Br J Haematol. 2021;195:310-327.
    PubMed     Abstract available

    October 2021
  97. NOSAKA K, Kusumoto S, Nakano N, Choi I, et al
    Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17895.
    PubMed     Abstract available

  98. LIU M, Zhao X, Pan W, Qian Z, et al
    A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy.
    Br J Haematol. 2021;195:e123-e128.

  99. BARTRAM J, Balasch-Carulla M, Bhojaraja S, Adams S, et al
    Blinatumomab for paediatric mixed phenotype acute leukaemia.
    Br J Haematol. 2021;195:289-292.

  100. EDWARDS K, Zaitseva K, Sayed U, Volpi EV, et al
    Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;195:e131-e134.

  101. TESTI AM, Mohamed S, Diverio D, Piciocchi A, et al
    Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.
    Br J Haematol. 2021;195:278-283.

  102. BEZDEKOVA R, Jelinek T, Kralova R, Stork M, et al
    Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
    Br J Haematol. 2021;195:95-107.
    PubMed     Abstract available

  103. GOULD C, Lickiss J, Kankanige Y, Yerneni S, et al
    Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
    Br J Haematol. 2021;195:113-118.
    PubMed     Abstract available

  104. THASTRUP M, Marquart HV, Levinsen M, Modvig S, et al
    Flow cytometric analysis of cerebrospinal fluid improves detection of leukaemic blasts in infants with acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:119-122.
    PubMed     Abstract available

  105. O'CONNOR D, Loke J, Brown M, Stanworth SJ, et al
    Non-pharmacological supportive-care interventions in acute myeloid leukaemia: a review of randomised controlled trials.
    Br J Haematol. 2021;195:e97-e113.

  106. MAENG CV, Ostgard LSG, Christiansen CF, Liu KD, et al
    Changes in intensive care unit admission rates, organ support, and mortality in patients with acute myeloid leukaemia over a 12-year period: a Danish nationwide cohort study.
    Br J Haematol. 2021;195:137-140.

    September 2021
  107. COOK LBM
    Adult T-cell leukaemia/lymphoma and the trouble with TP53.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17830.

  108. CHATTERJEE G, Sriram H, Ghogale S, Deshpande N, et al
    Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Br J Haematol. 2021 Sep 2. doi: 10.1111/bjh.17801.
    PubMed     Abstract available

  109. CHOWDHURY O, Bruguier H, Mallett G, Sousos N, et al
    Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
    Br J Haematol. 2021;194:1010-1015.

  110. HARRINGTON P, Doores KJ, Radia D, O'Reilly A, et al
    Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;194:999-1006.
    PubMed     Abstract available

  111. A special issue on modern genomics in diagnostic haematology.
    Br J Haematol. 2021;194:801-802.

  112. KUIPER RP, Hoogeveen PG, Bladergroen R, van Dijk F, et al
    Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all.
    Br J Haematol. 2021;194:888-892.
    PubMed     Abstract available

  113. KHAN M, Roddy JT, Hernandez JR, Bursch K, et al
    Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML.
    Br J Haematol. 2021;194:1083-1085.

  114. RASCHE A, Mason EF, Strickland SA, Byrne M, et al
    Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;194:927-931.

  115. ALCALDE-MELLADO P, Franco-Macias E, Morales-Camacho RM, Caballero-Velazquez T, et al
    Auer rod-like inclusions in cerebrospinal fluid in accelerated phase chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:946.

    August 2021
  116. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
    PubMed     Abstract available

  117. FANG H, Wang W, El Hussein S, Morita K, et al
    B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
    Br J Haematol. 2021 Aug 16. doi: 10.1111/bjh.17681.
    PubMed     Abstract available

  118. HENRY A, Bracquemart C, Naguib D, Chantepie S, et al
    Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.
    Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17761.

  119. PATEL PA, Lapp SA, Grubbs G, Edara VV, et al
    Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
    Br J Haematol. 2021;194:549-553.

  120. LUCCHINI G, Furness C, Lawson S, Gibson B, et al
    COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
    Br J Haematol. 2021;194:e74-e77.

  121. YEOH AEJ, Oh BL, Ariffin H
    Doing less, accomplishing more for childhood acute lymphoblastic leukaemia (ALL).
    Br J Haematol. 2021;194:661-662.

  122. NOURA M, Morita K, Kiyose H, Okuno Y, et al
    Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Kruppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) axis.
    Br J Haematol. 2021;194:598-603.
    PubMed     Abstract available

  123. RAMDENY PS, Mullanfroze K, de Lorenzo P, Grazia Valsecchi M, et al
    Infant T-cell acute lymphoblastic leukaemia with t(6;7) (TCRB-MYB) translocation.
    Br J Haematol. 2021;194:613-616.
    PubMed     Abstract available

  124. ROMZOVA M, Smitalova D, Hynst J, Tom N, et al
    Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
    Br J Haematol. 2021;194:604-612.
    PubMed     Abstract available

  125. MASLAH N, Diawara Y, Sebert M, Giraudier S, et al
    In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
    Br J Haematol. 2021;194:e77-e79.

  126. JENSEN KS, Oskarsson T, Lahteenmaki PM, Flaegstad T, et al
    Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population-based cohort study.
    Br J Haematol. 2021;194:734-744.
    PubMed     Abstract available

  127. CORNEAU A, Parizot C, Cherai M, Todesco E, et al
    Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
    Br J Haematol. 2021;194:788-792.

  128. ALLSUP D, Howard D, Emmerson J, Hockaday A, et al
    COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
    Br J Haematol. 2021;194:646-650.

  129. LOBO-OLMEDO A, Roldan Galiacho V, Arzuaga-Mendez J, Ancin I, et al
    Acute megakaryoblastic leukaemia with erythrophagocytosis.
    Br J Haematol. 2021;194:658.

    July 2021
  130. BRANVALL E, Ekberg S, Eloranta S, Wasterlid T, et al
    Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
    Br J Haematol. 2021 Jul 31. doi: 10.1111/bjh.17733.
    PubMed     Abstract available

  131. MOIA R, Favini C, Ferri V, Forestieri G, et al
    Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17718.
    PubMed     Abstract available

    What is the right dosage of dasatinib for treating chronic myeloid leukaemia?
    Br J Haematol. 2021;194:234.

  133. ROUSSELOT P, Mollica L, Guilhot J, Guerci A, et al
    Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
    Br J Haematol. 2021;194:393-402.
    PubMed     Abstract available

  134. NAKAMURA M, Arai Y, Hirabayashi S, Kondo T, et al
    Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.
    Br J Haematol. 2021;194:403-413.
    PubMed     Abstract available

  135. COMONT T, Meunier M, Cherait A, Santana C, et al
    Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    Br J Haematol. 2021;194:336-343.
    PubMed     Abstract available

  136. WIERNIK PH, Sun Z, Cripe LD, Rowe JM, et al
    Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia.
    Br J Haematol. 2021;194:309-318.
    PubMed     Abstract available

  137. ROEKER LE, Thompson MC, Mato AR
    Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice.
    Br J Haematol. 2021;194:9-10.

  138. MULRONEY CM, Abid MB, Bashey A, Chemaly RF, et al
    Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
    Br J Haematol. 2021;194:145-157.
    PubMed     Abstract available

  139. EYRE TA, Preston G, Kagdi H, Islam A, et al
    A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
    Br J Haematol. 2021;194:69-77.
    PubMed     Abstract available

  140. SASAKI K, Tsujimoto S, Miyake M, Uchiyama Y, et al
    Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
    Br J Haematol. 2021;194:414-422.
    PubMed     Abstract available

  141. SCOTT S, Cartwright A, Francis S, Whitby L, et al
    Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
    Br J Haematol. 2021;194:53-60.
    PubMed     Abstract available

  142. RADICH J
    Building a better mousetrap for accurate and sensitive polymerase chain reaction.
    Br J Haematol. 2021;194:11-13.

  143. SASSEN SDT, Mathot RAA, Pieters R, de Haas V, et al
    Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response.
    Br J Haematol. 2021;194:423-432.
    PubMed     Abstract available

  144. KOUKOULIAS K, Papadopoulou A, Kouimtzidis A, Papayanni PG, et al
    Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine.
    Br J Haematol. 2021;194:158-167.
    PubMed     Abstract available

  145. BODOR C, Kotmayer L, Laszlo T, Takacs F, et al
    Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
    Br J Haematol. 2021;194:355-364.
    PubMed     Abstract available

  146. MICHALOWSKI MB, Cecconello DK, Lins MM, Carvalho MDPSS, et al
    Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study.
    Br J Haematol. 2021;194:168-173.
    PubMed     Abstract available

  147. ZHAO Y, McCracken J, Rehder C, Wang E, et al
    Biclonal evolution of chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:e64-e66.

  148. CHERNG HJ, Jammal N, Paul S, Wang X, et al
    Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:61-68.
    PubMed     Abstract available

  149. DENNIS M, Burnett A, Hills R, Thomas I, et al
    A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
    Br J Haematol. 2021;194:298-308.
    PubMed     Abstract available

  150. POCOCK R, Farah N, Richardson SE, Mansour MR, et al
    Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;194:28-43.
    PubMed     Abstract available

  151. ASSANTO GM, Riemma C, Malaspina F, Perrone S, et al
    The current role of interferon in hairy cell leukaemia: clinical and molecular aspects.
    Br J Haematol. 2021;194:78-82.
    PubMed     Abstract available

  152. POPOV A, Fominikh V, Mikhailova E, Shelikhova L, et al
    Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants.
    Br J Haematol. 2021;194:174-178.
    PubMed     Abstract available

  153. KOLLA BC, Halim NAA, Cao Q, Sachs Z, et al
    High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
    Br J Haematol. 2021;194:140-144.
    PubMed     Abstract available

  154. HSU H, Roncolato F, Lee SH
    Lysosomal acid lipase deficiency diagnosed in a patient presenting with acute myeloid leukaemia.
    Br J Haematol. 2021;194:228.

  155. SHACKLETON L, McCarthy J, Mykytiv V
    Extramedullary pericardial haematopoiesis as a presenting feature of chronic myeloid leukaemia.
    Br J Haematol. 2021;194:7.

    June 2021
  156. OSTERGAARD J, Jonart LM, Ebadi M, Koppenhafer SL, et al
    Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17610.

  157. KARANTANOS T, Gondek LP, Varadhan R, Moliterno AR, et al
    Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Br J Haematol. 2021;193:1142-1150.
    PubMed     Abstract available

  158. XU R, Huang X, Li C, Deng C, et al
    Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/beta-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes.
    Br J Haematol. 2021;193:928-940.
    PubMed     Abstract available

  159. MOSKORZ W, Cosmovici C, Jager PS, Cadeddu RP, et al
    Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.
    Br J Haematol. 2021;193:941-945.
    PubMed     Abstract available

  160. CAO H, Neerincx A, de Bono B, Lakner U, et al
    Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.
    Br J Haematol. 2021;193:946-950.
    PubMed     Abstract available

  161. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    PubMed     Abstract available

  162. NISHIMURA A, Naruto T, Miyamoto S, Grigg A, et al
    Genomics analysis of leukaemia predisposition in X-linked agammaglobulinaemia.
    Br J Haematol. 2021;193:1277-1281.

  163. VAN DE GEER A, Zandstra J, Tanck MWT, Nur E, et al
    Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukaemia: a pilot study.
    Br J Haematol. 2021;193:1008-1012.

  164. SHAH MV, Saliba RM, Varma A, Ciurea SO, et al
    Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
    Br J Haematol. 2021;193:1004-1008.

  165. FLYGT H, Sandin F, Dahlen T, Dremaine A, et al
    Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
    Br J Haematol. 2021;193:915-921.
    PubMed     Abstract available

  166. WANG H, Zhou Y, Huang X, Zhang Y, et al
    Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1096-1104.
    PubMed     Abstract available

  167. CREUZET E, Nourrisson C, Chaleteix C, Poirier P, et al
    Cerebral aspergillosis in a patient on ibrutinib therapy.
    Br J Haematol. 2021;193:1025.

  168. DANDER E, Fallati A, Gulic T, Pagni F, et al
    Monocyte-macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1157-1171.
    PubMed     Abstract available

  169. TSAUR G, Popov A, Riger T, Kustanovich A, et al
    Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
    Br J Haematol. 2021;193:1151-1156.
    PubMed     Abstract available

  170. BRIVIO E, Chantrain CF, Gruber TA, Thano A, et al
    Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
    Br J Haematol. 2021;193:1172-1177.
    PubMed     Abstract available

  171. BRAS AE, Osmani Z, de Haas V, Jongen-Lavrencic M, et al
    Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia.
    Br J Haematol. 2021;193:922-927.
    PubMed     Abstract available

    May 2021
  172. CHANDER G, Nikolousis E, Kanellopoulos A
    Human papilloma virus (HPV)-associated lesions in a post-bone marrow transplant patient responding to HPV vaccination.
    Br J Haematol. 2021 May 2. doi: 10.1111/bjh.17514.

  173. ROSS DM
    How much imatinib is enough?
    Br J Haematol. 2021;193:699-700.

  174. KIM DDH, Novitzky-Basso I, Kim TS, Atenafu EG, et al
    Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
    Br J Haematol. 2021;193:779-791.
    PubMed     Abstract available

  175. KHARFAN-DABAJA MA, Labopin M, Brissot E, Kroger N, et al
    Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;193:592-601.
    PubMed     Abstract available

  176. AOKI K, Kurashige M, Ichii M, Higaki K, et al
    Identification of CXCL12-abundant reticular cells in human adult bone marrow.
    Br J Haematol. 2021;193:659-668.
    PubMed     Abstract available

  177. MIKHAILOVA E, Semchenkova A, Illarionova O, Kashpor S, et al
    Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
    Br J Haematol. 2021;193:602-612.
    PubMed     Abstract available

  178. SEMBILL S, Gohring G, Schirmer E, Lutterloh F, et al
    Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics.
    Br J Haematol. 2021;193:613-618.
    PubMed     Abstract available

  179. DE MIGUEL SANCHEZ C, Robles de Castro D, Pison Herrero C, Perez Persona E, et al
    Primary plasma cell leukaemia presenting with flower-shaped nuclei.
    Br J Haematol. 2021;193:689.

  180. CHEN D, Chen W
    Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
    Br J Haematol. 2021;193:691.

  181. NOY-LOTAN S, Krasnov T, Dgany O, Jeison M, et al
    Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
    Br J Haematol. 2021;193:570-580.
    PubMed     Abstract available

  182. HJORT JAKOBSEN L, Stidsholt Roug A, Kiesbye Ovlisen A, Werenberg Marcher C, et al
    Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study.
    Br J Haematol. 2021;193:482-487.
    PubMed     Abstract available

  183. SMOLEJ L
    Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
    Br J Haematol. 2021;193:723-726.
    PubMed     Abstract available

    April 2021
  184. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    PubMed     Abstract available

  185. ZHENG J, Wu S, Hu Y, Gao L, et al
    Management of ETV6-ABL1-positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action.
    Br J Haematol. 2021;193:197-200.

  186. GANESAN P, Jain H, Bagal B, Subramanian PG, et al
    Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC).
    Br J Haematol. 2021;193:e1-e4.

  187. FITTER S, Bradey AL, Kok CH, Noll JE, et al
    CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:171-175.
    PubMed     Abstract available

  188. TROUSSARD X, Grever MR
    The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant.
    Br J Haematol. 2021;193:11-14.

  189. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    PubMed     Abstract available

  190. SMOLEJ L, Turcsanyi P, Kubova Z, Zuchnicka J, et al
    External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.
    Br J Haematol. 2021;193:133-137.
    PubMed     Abstract available

  191. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    PubMed     Abstract available

  192. RASTOGI N, Baker S, Man S, Uger RA, et al
    Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
    Br J Haematol. 2021;193:155-159.
    PubMed     Abstract available

  193. GURNARI C, Breccia M, Di Giuliano F, Scalzulli E, et al
    Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.
    Br J Haematol. 2021;193:129-132.
    PubMed     Abstract available

  194. STILGENBAUER S, Bosch F, Ilhan O, Kisro J, et al
    Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Br J Haematol. 2021;193:325-338.
    PubMed     Abstract available

  195. DA CUNHA-BANG C, Rostgaard K, Andersen MA, Rotbain EC, et al
    Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
    Br J Haematol. 2021;193:339-345.
    PubMed     Abstract available

  196. SOVERINI S, Martelli M, Bavaro L, De Benedittis C, et al
    Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:271-279.
    PubMed     Abstract available

  197. CLAUDIANI S, Apperley JF, Szydlo R, Khan A, et al
    TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;193:346-355.
    PubMed     Abstract available

  198. DILLON R, Potter N, Freeman S, Russell N, et al
    How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).
    Br J Haematol. 2021;193:231-244.
    PubMed     Abstract available

    March 2021
    Flow cytometry reveals the nuances of clonal haematopoiesis.
    Br J Haematol. 2021;192:949-950.

  200. BECKER MW, Angelucci E
    A large co-operative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia.
    Br J Haematol. 2021;192:800-802.

  201. LOGHAVI S, DiNardo CD, Furudate K, Takahashi K, et al
    Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
    Br J Haematol. 2021;192:1054-1063.
    PubMed     Abstract available

  202. SCHLIEMANN C, Kessler T, Berdel AF, Hemmerle T, et al
    Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
    Br J Haematol. 2021;192:e148-e151.

  203. FERRARI A, Ghelli Luserna Di Rora A, Domizio C, Papayannidis C, et al
    Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
    Br J Haematol. 2021;192:e139-e144.

  204. RIGOLIN GM, Saccenti E, Melandri A, Cavallari M, et al
    In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.
    Br J Haematol. 2021;192:1068-1072.
    PubMed     Abstract available

  205. TIONG IS, Dillon R, Ivey A, Teh TC, et al
    Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
    Br J Haematol. 2021;192:1026-1030.
    PubMed     Abstract available

  206. QU S, Li B, Qin T, Xu Z, et al
    Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
    Br J Haematol. 2021;192:1006-1010.
    PubMed     Abstract available

  207. LUNDIN-STROM KB, Biloglav A, Lazarevic V, Behrendtz M, et al
    Parental origin of monosomy 7 in acute leukaemia.
    Br J Haematol. 2021;192:e132-e135.

  208. KAYSER S, Hills RK, Langova R, Kramer M, et al
    Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
    Br J Haematol. 2021;192:832-842.
    PubMed     Abstract available

    February 2021
  209. SMOLEJ L, Brychtova Y, Cmunt E, Doubek M, et al
    Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL St
    Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17373.
    PubMed     Abstract available

  210. WOUTERS Y, Nevejan L, Louwagie A, Devos H, et al
    Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
    Br J Haematol. 2021;192:e112-e115.

  211. WANG J
    Leukaemia blues - an unusual presentation of leukaemia cutis.
    Br J Haematol. 2021;192:676.

  212. GORDON MJ, Huang J, Chan RJ, Bhargava P, et al
    Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
    Br J Haematol. 2021;192:720-728.
    PubMed     Abstract available

  213. EGHOLM GJ, Andersen MA, Andersen CL, Frederiksen H, et al
    Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival.
    Br J Haematol. 2021;192:e81-e84.

  214. HOTINSKI AK, Best OG, Thurgood LA, Lower KM, et al
    A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Br J Haematol. 2021;192:e77-e81.

  215. ALI AM, Cooper J, Walker A, Jones D, et al
    Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL.
    Br J Haematol. 2021;192:665-667.

  216. BRAUNSTEIN Z, Mishra A, Staub A, Freud AG, et al
    Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.
    Br J Haematol. 2021;192:484-493.
    PubMed     Abstract available

  217. FLOETH M, Elges S, Gerss J, Schwoppe C, et al
    Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2021;192:494-503.
    PubMed     Abstract available

  218. MORENO BERGGREN D, Kjellander M, Backlund E, Engvall M, et al
    Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2021;192:474-483.
    PubMed     Abstract available

  219. DIAMANTI P, Ede BC, Dace PE, Barendt WJ, et al
    Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
    Br J Haematol. 2021;192:577-588.
    PubMed     Abstract available

    January 2021
  220. AKINOSOGLOU K, Paliogianni F, Spyridonidis A, Symeonidis A, et al
    SARS-CoV-2 persistence and non-protective immunity in infected haematological patients.
    Br J Haematol. 2021;192:e51-e54.

  221. BRECCIA M
    Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:237-238.

  222. ROSS DM, Hughes TP
    Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge.
    Br J Haematol. 2021;192:24-27.
    PubMed     Abstract available

  223. KARAGIANNIS P, Alsdorf W, Tallarek AC, Blohm ME, et al
    Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
    Br J Haematol. 2021;192:e60-e63.

  224. FOUZIA NA, Sharma V, Ganesan S, Palani HK, et al
    Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
    Br J Haematol. 2021;192:292-299.
    PubMed     Abstract available

  225. JIN W, Chen L, Liu Y, Chen Q, et al
    A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:e32-e36.

  226. OTTAVIANO G, Baird S, Bonney D, Connor P, et al
    The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
    Br J Haematol. 2021;192:e42-e44.

  227. CAVALLINI C, Galasso M, Pozza ED, Chignola R, et al
    Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    Br J Haematol. 2021;192:333-342.
    PubMed     Abstract available

  228. GALE RP, Saglio G
    Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?
    Br J Haematol. 2021;192:22-23.

  229. MATSUO H, Wakita T, Hiramatsu H, Ohmori K, et al
    Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
    Br J Haematol. 2021;192:e7-e11.

  230. MASON CC, Fiol CR, Baker MJ, Nadal-Melsio E, et al
    Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
    Br J Haematol. 2021;192:137-145.
    PubMed     Abstract available

  231. FRISANCO OLIVEIRA A, Tansini A, Toledo TR, Balceiro R, et al
    Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
    Br J Haematol. 2021;192:129-136.
    PubMed     Abstract available

  232. RADICH J
    Molecular testing of chronic myeloid leukaemia in low resource areas.
    Br J Haematol. 2021;192:28-32.
    PubMed     Abstract available

  233. DUAN W, Liu X, Jia J, Wang J, et al
    The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
    Br J Haematol. 2021;192:265-271.
    PubMed     Abstract available

  234. MILOJKOVIC D, Cross NCP, Ali S, Byrne J, et al
    Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
    Br J Haematol. 2021;192:62-74.
    PubMed     Abstract available

    December 2020
  235. NAKAHATA S, Morishita K
    Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Dec 14. doi: 10.1111/bjh.17214.

  236. NELSON ND, McMahon CM, El-Sharkawy Navarro F, Freyer CW, et al
    Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia.
    Br J Haematol. 2020;191:935-938.

  237. CHEN J, Wang F, Fang J, Nie D, et al
    Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing.
    Br J Haematol. 2020;191:e113-e116.

  238. PARRY-JONES N, Joshi A, Forconi F, Dearden C, et al
    Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V).
    Br J Haematol. 2020;191:730-737.

  239. GANGAT N, Morsia E, Foran JM, Palmer JM, et al
    Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients.
    Br J Haematol. 2020;191:e120-e124.

  240. MOORMAN AV, Schwab C, Winterman E, Hancock J, et al
    Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
    Br J Haematol. 2020;191:844-851.
    PubMed     Abstract available

  241. MERYK A, Kropshofer G, Hutter J, Fritz J, et al
    Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia.
    Br J Haematol. 2020;191:816-824.
    PubMed     Abstract available

  242. SIBAI H, Chen R, Liu X, Falcone U, et al
    Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
    Br J Haematol. 2020;191:748-754.
    PubMed     Abstract available

  243. FRISCH A, Rowe JM, Ofran Y
    How we treat older patients with acute myeloid leukaemia.
    Br J Haematol. 2020;191:682-691.
    PubMed     Abstract available

    November 2020
  244. ZHANG X, Suo S, Wang J, Jin J, et al
    IDH1(R132S) -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
    Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17199.

  245. SAKAMOTO Y, Ishida T, Masaki A, Takeshita M, et al
    Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Nov 18. doi: 10.1111/bjh.17211.
    PubMed     Abstract available

  246. MONDELLO P, Zelenetz AD
    Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy.
    Br J Haematol. 2020;191:326-328.

  247. CHAGALUKA G, Schwalbe EC, Chakumatha E, Carey P, et al
    Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low-income setting - the Blantyre experience.
    Br J Haematol. 2020;191:e87-e90.

  248. CASSADAY RD, Marks DI, DeAngelo DJ, Jabbour EJ, et al
    Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
    Br J Haematol. 2020;191:e77-e81.

  249. TUEUR G, Lazarian G, Eclache V, Fleury C, et al
    Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort.
    Br J Haematol. 2020;191:e90-e94.

  250. MATTSSON A, Sylvan SE, Asklid A, Wiggh J, et al
    Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
    Br J Haematol. 2020;191:426-432.
    PubMed     Abstract available

  251. DERRIEUX C, Gish A, Caulier A, Grardel N, et al
    Shared clonal IGH rearrangement in BCP-ALL occurring after CLL: pitfalls and implications for MRD monitoring.
    Br J Haematol. 2020;191:506-509.

  252. IRANI YD, Hughes A, Clarson J, Kok CH, et al
    Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
    Br J Haematol. 2020;191:433-441.
    PubMed     Abstract available

    October 2020
  253. HERISHANU Y, Levi S, Kamdjou T, Bornstein Y, et al
    Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
    Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17105.

  254. FOX TA, Troy-Barnes E, Kirkwood AA, Chan WY, et al
    Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
    Br J Haematol. 2020;191:194-206.
    PubMed     Abstract available

  255. CLARK RE
    Another set of guidelines for chronic myeloid leukaemia.
    Br J Haematol. 2020;191:147-149.

  256. GILLEECE MH, Savani BN
    A stitch in time saves nine... MRD-based pre-emptive therapy.
    Br J Haematol. 2020;191:19-20.

  257. BO A, Raiola AM, Gualandi F, Orengo G, et al
    Unintentional human leukocyte antigen-mismatched haematopoietic cell transplant: clinical course and root cause analysis.
    Br J Haematol. 2020;191:e35-e37.

  258. MONTORO J, Chorao P, Quintero A, Roca J, et al
    Male genital GvHD: a hidden complication following haematopoietic stem cell transplantation.
    Br J Haematol. 2020;191:12.

  259. SMITH G, Apperley J, Milojkovic D, Cross NCP, et al
    A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.
    Br J Haematol. 2020;191:171-193.

  260. MCCLURE BJ, Heatley SL, Rehn J, Breen J, et al
    High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse.
    Br J Haematol. 2020;191:301-304.

  261. RASHIDI A, Kaiser T, Ebadi M, Holtan SG, et al
    Circulating bacterial DNA and neutropenic fever during anti-leukaemia chemotherapy.
    Br J Haematol. 2020;191:e55-e58.

  262. DONG S, Khedro T, Ward P, Dubeau L, et al
    First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia.
    Br J Haematol. 2020;191:e52-e55.

  263. KONG D, Qu C, Dai H, Li Z, et al
    CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph(+) mixed phenotype acute leukaemia with minimal residual disease.
    Br J Haematol. 2020;191:e47-e49.

  264. KHALIFE R, Montroy J, Grigor EJM, Fergusson DA, et al
    Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study.
    Br J Haematol. 2020;191:e14-e19.

  265. PAUL S, Jammal N, Akhave N, Aung PP, et al
    Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia.
    Br J Haematol. 2020;191:e10-e13.

  266. CERRANO M, Castella B, Lia G, Olivi M, et al
    Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:e28-e32.

  267. RYLAND GL, Barraclough A, Fong CY, Fleming S, et al
    Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:123-126.

  268. ZABKIEWICZ J, Lazenby M, Edwards G, Bygrave CA, et al
    Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
    Br J Haematol. 2020;191:231-242.
    PubMed     Abstract available

  269. WANG J, Mou N, Yang Z, Li Q, et al
    Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:212-222.
    PubMed     Abstract available

  270. GANZEL C, Wang XV, Rowe JM, Richards SM, et al
    At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.
    Br J Haematol. 2020;191:37-43.
    PubMed     Abstract available

    September 2020
  271. ORF K, Rogosic S, Dexter D, Ancliff P, et al
    Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.
    Br J Haematol. 2020;190:e274-e276.

  272. SILLA L
    Double-bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2.
    Br J Haematol. 2020;190:e322-e323.

  273. NESR G, Koshy R, Foldes D, Kagdi H, et al
    Autoimmune haemolytic anaemia and a marked rise in the lymphocyte count associated with COVID-19 in a patient with treatment-naive chronic lymphocytic leukaemia: a case report.
    Br J Haematol. 2020;190:e326-e328.

  274. SMOLEJ L
    Incidence and prognostic significance of serum immunoglobulins and paraproteins in patients with chronic lymphocytic leukaemia: another valuable piece of the puzzle.
    Br J Haematol. 2020;190:815-816.

  275. EYRE TA
    Prognostication in Richter syndrome: context is everything.
    Br J Haematol. 2020;190:811-812.

  276. CORBINGI A, Innocenti I, Tomasso A, Pasquale R, et al
    Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;190:901-908.
    PubMed     Abstract available

  277. SHOUMARIYEH K, Hussung S, Niemoller C, Bleul S, et al
    Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT.
    Br J Haematol. 2020;190:e339-e343.

  278. DE PROPRIS MS, Intoppa S, Milani ML, Mariglia P, et al
    ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;190:e346-e349.

  279. SAITO Y, Makita S, Chinen S, Kito M, et al
    Acute megakaryoblastic leukaemia with t(1;22)(p13.3;q13.1)/RBM15-MKL1 in an adult patient following a non-mediastinal germ cell tumour.
    Br J Haematol. 2020;190:e329-e332.

  280. BRECCIA M, Vignetti M, Annibali O, Cottone F, et al
    Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning.
    Br J Haematol. 2020;190:e304-e307.

  281. FOX LC, Tan M, Brown AL, Arts P, et al
    A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability.
    Br J Haematol. 2020;190:e297-e301.

  282. YAMANE T, Kawakami T, Sekiguchi N, Kobayashi J, et al
    High frequency of STAT3 gene mutations in T-cell receptor (TCR)gammadelta-type T-cell large granular lymphocytic leukaemia: implications for molecular diagnostics.
    Br J Haematol. 2020;190:e301-e304.

  283. HANEKAMP D, Snel AN, Kelder A, Scholten WJ, et al
    Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
    Br J Haematol. 2020;190:891-900.
    PubMed     Abstract available

  284. OFFNER F, Robak T, Janssens A, Govind Babu K, et al
    A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
    Br J Haematol. 2020;190:736-740.
    PubMed     Abstract available

  285. TURKINA A, Wang J, Mathews V, Saydam G, et al
    TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries.
    Br J Haematol. 2020;190:869-876.
    PubMed     Abstract available

  286. VARGHESE AM, Sood N, Daniel SM
    Current pricing model for cancer drugs - is it 'Justum Pretium' for the developing world? Taking management of chronic lymphocytic leukaemia in India into consideration.
    Br J Haematol. 2020;190:e292-e294.

  287. EL CHAER F, Ballen KK
    Treatment of acute leukaemia in adult Jehovah's Witnesses.
    Br J Haematol. 2020;190:696-707.
    PubMed     Abstract available

    August 2020
  288. RANGER A, Haji R, Kaczmarski R, Danga A, et al
    Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
    Br J Haematol. 2020;190:e128-e130.

  289. PICIOCCHI A, Messina M, Soddu S, La Sala E, et al
    The COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.
    Br J Haematol. 2020;190:e211-e214.

  290. FARAH N, Burt R, Ibrahim AR, Baker R, et al
    Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
    Br J Haematol. 2020;190:e208-e210.

  291. CHOPRA J, Hiew HJ, Cumpstey A, Cagampang F, et al
    Successful treatment of chronic myelomonocytic leukaemia with hydroxycarbamide in a patient presenting with acute hypoxic respiratory failure due to COVID-19 pneumonia.
    Br J Haematol. 2020;190:e195-e198.

  292. INNES AJ, Cook LB, Marks S, Bataillard E, et al
    Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
    Br J Haematol. 2020;190:e198-e200.

  293. WILSON AJ, Troy-Barnes E, Subhan M, Clark F, et al
    Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.
    Br J Haematol. 2020;190:e189-e191.

  294. FARMER I, Okikiolu J, Steel M, Wanniarachchi C, et al
    Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum.
    Br J Haematol. 2020;190:e248-e250.

  295. LEISCH M, Greil R, Pleyer L
    IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
    Br J Haematol. 2020;190:314-317.

  296. ANDREWS C, Maze D, Murphy T, Sibai H, et al
    Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
    Br J Haematol. 2020;190:467-470.

  297. ZHU J, Raimbault A, Sourdeau E, Maillon A, et al
    Holding on to the Matutes score while dropping FMC7: new opportunity from standardised approaches in multiparameter flow cytometry.
    Br J Haematol. 2020;190:e255-e258.

  298. GLAVEY SV, Flanagan L, Bleach R, Kelly C, et al
    Secondary plasma cell leukaemia treated with single agent venetoclax.
    Br J Haematol. 2020;190:e242-e245.

  299. CHOWDHURY A, Loaiza S, Yebra-Fernandez E, Nadal-Melsio E, et al
    An ex vivo investigation of interactions between primary acute myeloid leukaemia and mesenchymal stromal cells yields novel therapeutic targets.
    Br J Haematol. 2020;190:e236-e239.

  300. FIEDLER W, Chromik J, Amberg S, Kebenko M, et al
    A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
    Br J Haematol. 2020;190:e169-e173.

  301. NIE D, Zhang J, Xiong M, Wang F, et al
    Complete remission of refractory juvenile acute myeloid leukaemia with RUNX1-PRDM16 in Bloom syndrome after haematopoietic stem cell transplantation.
    Br J Haematol. 2020;190:e166-e169.

  302. PETERLIN P, Cluzeau T, Jullien M, Ngo Nloga AM, et al
    Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
    Br J Haematol. 2020;190:461-464.

  303. LOKE J, Lowe DM, Miller LJ, Morton S, et al
    Supportive care in the management of patients with acute myeloid leukaemia: where are the research needs?
    Br J Haematol. 2020;190:311-313.

  304. LEBLANC FR, Pearson JM, Tan SF, Cheon H, et al
    Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.
    Br J Haematol. 2020;190:405-417.
    PubMed     Abstract available

  305. WANG J, Lu R, Wu Y, Jia J, et al
    Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Br J Haematol. 2020;190:533-544.
    PubMed     Abstract available

  306. WILHELMSON AS, Porse BT
    CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.
    Br J Haematol. 2020;190:495-507.
    PubMed     Abstract available

  307. SAGLIO G, Gale RP
    Prospects for achieving treatment-free remission in chronic myeloid leukaemia.
    Br J Haematol. 2020;190:318-327.
    PubMed     Abstract available

  308. HERUDKOVA Z, Culen M, Folta A, Jeziskova I, et al
    Clonal hierarchy of main molecular lesions in acute myeloid leukaemia.
    Br J Haematol. 2020;190:562-572.
    PubMed     Abstract available

    July 2020
  309. GESTRICH CK, Sadri N, Sinno MG, Pateva I, et al
    Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
    Br J Haematol. 2020 Jul 29. doi: 10.1111/bjh.17000.

  310. BLENNERHASSETT R, Kwan J, Coyle L, Wong K, et al
    Adult B- and T-lymphoblastic lymphoma treated with a paediatric acute lymphoblastic leukaemia regimen have excellent outcomes-a short report from two Sydney centres.
    Br J Haematol. 2020 Jul 28. doi: 10.1111/bjh.16998.

  311. BARNEA SLONIM L, Ma S, Behdad A, Chen Q, et al
    Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
    Br J Haematol. 2020 Jul 17. doi: 10.1111/bjh.16948.

  312. YANG Y, Juskevicius R
    T-lymphoblastic leukaemia/lymphoma with rosettes and gland-like structures.
    Br J Haematol. 2020 Jul 7. doi: 10.1111/bjh.16929.

  313. FOA R, Bonifacio M, Chiaretti S, Curti A, et al
    Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study.
    Br J Haematol. 2020;190:e3-e5.

  314. DAY JW, Fox TA, Halsey R, Carpenter B, et al
    Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
    Br J Haematol. 2020;190:e80-e83.

  315. KRUG U, Berdel WE
    Smoking and AML - another piece in the puzzle.
    Br J Haematol. 2020;190:143.

  316. MALAGOLA M, Bernardi S, Polverelli N, Russo D, et al
    Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?
    Br J Haematol. 2020;190:135-136.

  317. BARON F, Savani BN
    Graft-versus-host-disease does not help acute lymphoblastic leukaemia patients with measurable residual disease.
    Br J Haematol. 2020;190:22-23.

  318. ARMAND P, Murawski N, Molin D, Zain J, et al
    Pembrolizumab in relapsed or refractory Richter syndrome.
    Br J Haematol. 2020;190:e117-e120.

  319. CALVO C, Cabannes-Hamy A, Adjaoud D, Bruno B, et al
    Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;190:e53-e56.

  320. KAUR U, Gambhir IS, Khare VR, Singh A, et al
    Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukaemia.
    Br J Haematol. 2020;190:e51-e53.

  321. KRISTENSEN D, Nielsen LB, Roug AS, Kristensen TC, et al
    The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study.
    Br J Haematol. 2020;190:236-243.
    PubMed     Abstract available

  322. REA B, Bailey NG
    Acute myeloid leukaemia with t(8;16)(p11.2;p13.3) and erythrophagocytosis.
    Br J Haematol. 2020;190:133.

  323. JUUL-DAM KL, Ommen HB, Nyvold CG, Walter C, et al
    Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
    Br J Haematol. 2020;190:198-208.
    PubMed     Abstract available

  324. BENEFORTI L, Dander E, Bresolin S, Bueno C, et al
    Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche.
    Br J Haematol. 2020;190:262-273.
    PubMed     Abstract available

  325. ZHOU YL, Wu LX, Peter Gale R, Wang ZL, et al
    Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD).
    Br J Haematol. 2020;190:274-283.
    PubMed     Abstract available

  326. ZHANG JM, Xu Y, Gale RP, Wu LX, et al
    DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;190:67-78.
    PubMed     Abstract available

    June 2020
  327. FAVRESSE J, Eucher C, Elsen M, Graux C, et al
    Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia.
    Br J Haematol. 2020 Jun 17. doi: 10.1111/bjh.16954.
    PubMed     Abstract available

  328. YANG LH, Zhao Y, Maule J, Rapisardo S, et al
    T-lymphoblastic lymphoma and acute myeloid leukaemia transformed from myeloid neoplasm with eosinophilia: a divergent evolution of myeloid neoplasm with monosomy 7 but no detectable tyrosine kinase gene rearrangements designated by the WHO Classificat
    Br J Haematol. 2020 Jun 11. doi: 10.1111/bjh.16886.

  329. ABRISQUETA P, Delgado J, Alcoceba M, Oliveira AC, et al
    Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).
    Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16748.
    PubMed     Abstract available

  330. LARSSON K, Mattsson M, Ebrahim F, Glimelius I, et al
    High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16859.

  331. BATALLER A, Onate G, Diaz-Beya M, Guijarro F, et al
    Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
    Br J Haematol. 2020 Jun 8. doi: 10.1111/bjh.16857.
    PubMed     Abstract available

  332. WILLAN J, King AJ, Djebbari F, Turner GDH, et al
    Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID-19 pandemic.
    Br J Haematol. 2020;189:e224-e227.

  333. SIENI E, Pegoraro F, Casini T, Tondo A, et al
    Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression.
    Br J Haematol. 2020;189:e222-e224.

  334. LANGERAK AW, Davi F, Stamatopoulos K
    Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?
    Br J Haematol. 2020;189:809-810.

  335. STAHL M, Tallman MS
    Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML- A strong case for allogeneic stem cell transplantation in first complete remission.
    Br J Haematol. 2020;189:806-808.

  336. RAEDLER J, Heyde S, Kolokythas M, Eichinger A, et al
    Venetoclax and decitabine for relapsed paediatric myelodysplastic syndrome-related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation.
    Br J Haematol. 2020;189:e251-e254.

  337. DHAMI SPS, Tirincsi A, Baev D, Krawczyk J, et al
    Theranostic drug test incorporating the bone-marrow microenvironment can predict the clinical response of acute myeloid leukaemia to chemotherapy.
    Br J Haematol. 2020;189:e254-e258.

  338. LI XY, Qian JJ, Yang M, Zhang Y, et al
    An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e231-e234.

  339. DE FIGUEIREDO AF, Land MGP, Ferreira GM, Mencalha A, et al
    Clinical and biological correlates of the expression of select Polycomb complex genes in Brazilian children with acute promyelocytic leukaemia.
    Br J Haematol. 2020;189:e245-e248.

  340. WU X, Zhang J, Chen Q, Zhou L, et al
    Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
    Br J Haematol. 2020;189:e200-e204.

  341. GONG Z, Zhou T, Liu H, Tang G, et al
    Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia.
    Br J Haematol. 2020;189:e207-e211.

  342. ZHANG J, Wang Y, Li SQ, Fang L, et al
    Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models.
    Br J Haematol. 2020;189:1141-1150.
    PubMed     Abstract available

  343. LADIKOU EE, Chevassut T, Pepper CJ, Pepper AG, et al
    Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Br J Haematol. 2020;189:815-825.
    PubMed     Abstract available

  344. RAPONI S, Ilari C, Della Starza I, Cappelli LV, et al
    Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
    Br J Haematol. 2020;189:853-859.
    PubMed     Abstract available

  345. DIAZ-BEYA M, Labopin M, Maertens J, Alijurf M, et al
    Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
    Br J Haematol. 2020;189:920-925.
    PubMed     Abstract available

  346. AL-ALI HK, Griesshammer M, Foltz L, Palumbo GA, et al
    Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Br J Haematol. 2020;189:888-903.
    PubMed     Abstract available

  347. PATEL BJ, Barot SV, Kuzmanovic T, Kerr C, et al
    Distinctive and common features of moderate aplastic anaemia.
    Br J Haematol. 2020;189:967-975.
    PubMed     Abstract available

    May 2020
  348. THIBAUD S, Tremblay D, Bhalla S, Zimmerman B, et al
    Protective Role of BTK Inhibitors in Patients with Chronic Lymphocytic Leukemia and COVID-19.
    Br J Haematol. 2020 May 20. doi: 10.1111/bjh.16863.
    PubMed     Abstract available

  349. WU Y, Lin H, Xie Q, Chen Q, et al
    COVID-19 in a patient with pre-existing acute lymphoblastic leukemia.
    Br J Haematol. 2020 May 7. doi: 10.1111/bjh.16799.
    PubMed     Abstract available

  350. BALDACINI M, Pop R, Sattler L, Mauvieux L, et al
    Concomitant hemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukemia.
    Br J Haematol. 2020 May 5. doi: 10.1111/bjh.16768.
    PubMed     Abstract available

  351. ANTELO G, Mangaonkar AA, Coltro G, Buradkar A, et al
    Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
    Br J Haematol. 2020;189:e104-e108.

  352. GU X, Saunthararajah Y
    Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukaemia is obscured by paraformaldehyde fixation.
    Br J Haematol. 2020;189:578-581.

    Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?
    Br J Haematol. 2020;189:603-604.

  354. RAYMOND LM, Funk T, Braziel RM, Fan G, et al
    Mast cell sarcoma with concurrent mast cell leukaemia.
    Br J Haematol. 2020;189:e160-e164.

  355. ADELAIDE J, Cervera N, Guille A, Murati A, et al
    Gains of EPOR and ERG genes in adult erythroleukaemia.
    Br J Haematol. 2020;189:e174-e177.

  356. INABA H, Cao X, Chang JY, Karol SE, et al
    Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e177-e181.

  357. GIUSTI GNN, Jotta PY, Lopes CO, Ganazza MA, et al
    Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e150-e154.

  358. ROBINSON SE, Harrison CN
    How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
    Br J Haematol. 2020;189:625-634.
    PubMed     Abstract available

  359. PRIETO-CONDE MI, Jimenez C, Garcia-Alvarez M, Ramos F, et al
    Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients.
    Br J Haematol. 2020;189:718-730.
    PubMed     Abstract available

  360. ONECHA E, Ruiz-Heredia Y, Martinez-Cuadron D, Barragan E, et al
    Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
    Br J Haematol. 2020;189:672-683.
    PubMed     Abstract available

  361. UDEN T, Bertaina A, Abrahamsson J, Ansari M, et al
    Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.
    Br J Haematol. 2020;189:745-750.
    PubMed     Abstract available

  362. MIKLOS U, Strugov V, Lewerin C, Grosicki S, et al
    Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
    Br J Haematol. 2020;189:689-693.
    PubMed     Abstract available

  363. CICIARELLO M, Curti A
    Good news for acute myeloid leukaemia patients from the stroll niche?
    Br J Haematol. 2020;189:597-599.

  364. CHEN X, Chen H
    BCR-ABL1-positive acute myeloid leukaemia relapsing as acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:591.

  365. JIANG Y, Li Y, Cheng J, Ma J, et al
    Upregulation of AKR1C1 in mesenchymal stromal cells promotes the survival of acute myeloid leukaemia cells.
    Br J Haematol. 2020;189:694-706.
    PubMed     Abstract available

  366. ZHAO Y, Maule J, McCracken J, Li Y, et al
    Acute myeloid leukaemia with maturation demonstrates persistent disease with prominent megakaryoblastic differentiation 16 days following induction chemotherapy: an intra-myeloid lineage switch mediated by chemotherapy-induced clonal selection.
    Br J Haematol. 2020;189:e64-e67.

  367. DULUCQ S, Astrugue C, Etienne G, Mahon FX, et al
    Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.
    Br J Haematol. 2020;189:452-468.
    PubMed     Abstract available

  368. JORDAENS S, Cooksey L, Bonney S, Orchard L, et al
    Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:500-512.
    PubMed     Abstract available

  369. DELVECCHIO VS, Sana I, Mantione ME, Vilia MG, et al
    Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis.
    Br J Haematol. 2020;189:475-488.
    PubMed     Abstract available

  370. MARAJ A, MacEneaney O, Doyle B, Quinn J, et al
    Lysozyme-induced nephropathy: a rare manifestation of chronic myelomonocytic leukaemia.
    Br J Haematol. 2020;189:393.

  371. LINCH DC, Hills RK, Burnett AK, Gale RE, et al
    The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.
    Br J Haematol. 2020;189:e81-e86.

    ALL the comforts of homing: lymphoblasts find cerebrospinal fluid inhospitable without meningeal cell contact.
    Br J Haematol. 2020;189:395-397.

  373. VAN DER STRATEN L, Levin MD, Visser O, Posthuma EFM, et al
    Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016.
    Br J Haematol. 2020;189:574-577.

  374. BASILE P, Jonart LM, Ebadi M, Johnson K, et al
    The meninges enhance leukaemia survival in cerebral spinal fluid.
    Br J Haematol. 2020;189:513-517.
    PubMed     Abstract available

  375. KLOOS R, van der Sluis IM, Mastrobattista E, Hennink W, et al
    Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker.
    Br J Haematol. 2020;189:442-451.
    PubMed     Abstract available

    April 2020
  376. AOKI T, Takahashi H, Tanaka S, Shiba N, et al
    Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2020 Apr 26. doi: 10.1111/bjh.16656.
    PubMed     Abstract available

  377. FUSTER JL, Molinos-Quintana A, Fuentes C, Fernandez JM, et al
    Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).
    Br J Haematol. 2020 Apr 21. doi: 10.1111/bjh.16647.
    PubMed     Abstract available

  378. COGLE CR, Collins B, Turner D, Pettiford LC, et al
    Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
    Br J Haematol. 2020 Apr 1. doi: 10.1111/bjh.16629.

  379. DHOLARIA B, Savani BN
    Allogeneic haematopoietic cell transplantation after CAR T-cell therapy: safe, effective and contentious.
    Br J Haematol. 2020;189:21-23.

  380. BERTOLI S, Rieu JB, Recher C, Vergez F, et al
    Large granular lymphocytosis during quizartinib therapy.
    Br J Haematol. 2020;189:7.

  381. EBADI M, Beckman AK, Yohe SL, Rashidi A, et al
    It's all in the film.
    Br J Haematol. 2020;189:8.

  382. OSTERROOS A, Eriksson A, Antunovic P, Cammenga J, et al
    Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged >/= 60 years.
    Br J Haematol. 2020;189:e13-e16.

  383. GODWIN CD, Bates OM, Garling EE, Beddoe ME, et al
    The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.
    Br J Haematol. 2020;189:e9-e13.

  384. XU X, Zeng Z, Huo L, Liu H, et al
    High expression of myocyte enhancer factor 2C predicts poor prognosis for adult acute myeloid leukaemia with normal karyotype.
    Br J Haematol. 2020;189:e23-e27.

  385. ZHANG Y, Chen H, Song Y, Tan X, et al
    Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.
    Br J Haematol. 2020;189:146-152.
    PubMed     Abstract available

  386. ROESSNER PM, Hanna BS, Ozturk S, Schulz R, et al
    TBET-expressing Th1 CD4(+) T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in Emicro-TCL1 mice.
    Br J Haematol. 2020;189:133-145.
    PubMed     Abstract available

  387. WANG Y, Liu QF, Wu DP, Xu LP, et al
    Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients.
    Br J Haematol. 2020;189:153-161.
    PubMed     Abstract available

  388. YANG RY, Yang CX, Lang XP, Duan LJ, et al
    Identification of a novel RUNX1-TACC1 fusion transcript in acute myeloid leukaemia.
    Br J Haematol. 2020;189:e52-e56.

  389. DO YR, Kwak JY, Kim JA, Kim HJ, et al
    Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).
    Br J Haematol. 2020;189:303-312.
    PubMed     Abstract available

  390. ROSSOFF J, Huynh V, Rau RE, Macy ME, et al
    Experience with ponatinib in paediatric patients with leukaemia.
    Br J Haematol. 2020;189:363-368.
    PubMed     Abstract available

  391. AWADA H, Mahfouz RZ, Durrani J, Kishtagari A, et al
    Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation.
    Br J Haematol. 2020;189:318-322.
    PubMed     Abstract available

  392. FRAZZI R, Bizzarri V, Albertazzi L, Cusenza VY, et al
    Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;189:e49-e52.

  393. BANKAR A, Korula A, Kulkarni UP, Devasia AJ, et al
    Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
    Br J Haematol. 2020;189:269-278.
    PubMed     Abstract available

  394. PIETTE C, Suciu S, Bertrand Y, Uyttebroeck A, et al
    Long-term outcome evaluation of medium/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study.
    Br J Haematol. 2020;189:351-362.
    PubMed     Abstract available

    March 2020
  395. TOUW IP, Sanders MA
    Mutant allelic burden in acute myeloid leukaemia: Why bother?
    Br J Haematol. 2020;188:817-818.

  396. RICHARDSON AI, Skikne BS, Woodroof J
    Chronic myeloid leukaemia, BCR-ABL1-positive, in accelerated phase with marked eosinophilia with eosinophil atypia.
    Br J Haematol. 2020;188:599.

  397. RADIA DH, Green A, Oni C, Moonim M, et al
    The clinical and pathological panoply of systemic mastocytosis.
    Br J Haematol. 2020;188:623-640.
    PubMed     Abstract available

  398. XUE YJ, Suo P, Huang XJ, Lu AD, et al
    Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic le
    Br J Haematol. 2020;188:757-767.
    PubMed     Abstract available

  399. PALOMO L, Ibanez M, Abaigar M, Vazquez I, et al
    Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
    Br J Haematol. 2020;188:605-622.
    PubMed     Abstract available

  400. KNOFLER R, Lange BS, Paul F, Tiebel O, et al
    Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children.
    Br J Haematol. 2020;188:701-706.
    PubMed     Abstract available

  401. KIM YA, Ju HY, Park HJ, Lee NY, et al
    Outcomes of acute lymphoblastic leukaemia in adolescent and young adult Korean patients.
    Br J Haematol. 2020;188:740-744.
    PubMed     Abstract available

  402. CUCCHI DGJ, Bachas C, Klein K, Huttenhuis S, et al
    TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia.
    Br J Haematol. 2020;188:736-739.
    PubMed     Abstract available

  403. ZHAO C, Jia B, Wang M, Schell TD, et al
    Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.
    Br J Haematol. 2020;188:674-684.
    PubMed     Abstract available

  404. CHIN-YEE B, Sadikovic B, Chin-Yee IH
    Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:652-660.
    PubMed     Abstract available

  405. GIONA F, Malaspina F, Putti MC, Ladogana S, et al
    Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.
    Br J Haematol. 2020;188:e101-e105.

  406. GAUR V, Chaudhary S, Tyagi A, Agarwal S, et al
    Dysregulation of miRNA expression and their prognostic significance in paediatric cytogenetically normal acute myeloid leukaemia.
    Br J Haematol. 2020;188:e90-e94.

  407. VAN DER STRATEN L, Levin MD, Visser O, Blijlevens NMA, et al
    The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
    Br J Haematol. 2020;188:e109-e112.

    Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:844-851.
    PubMed     Abstract available

  409. ZHOU C, Zhuang Y, Lin X, Michelson AD, et al
    Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis.
    Br J Haematol. 2020;188:945-961.
    PubMed     Abstract available

  410. HOLTZMAN NG, El Chaer F, Baer MR, Ali O, et al
    Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia.
    Br J Haematol. 2020;188:881-887.
    PubMed     Abstract available

  411. ELSTON L, Fegan C, Hills R, Hashimdeen SS, et al
    Increased frequency of CD4(+) PD-1(+) HLA-DR(+) T cells is associated with disease progression in CLL.
    Br J Haematol. 2020;188:872-880.
    PubMed     Abstract available

  412. EYRE TA, Roeker LE, Fox CP, Gohill SH, et al
    The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:918-923.
    PubMed     Abstract available

  413. LINCH DC, Hills RK, Burnett AK, Russell N, et al
    Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.
    Br J Haematol. 2020;188:852-859.
    PubMed     Abstract available

    February 2020
  414. DALAL NH, Dores GM, Curtis RE, Linet MS, et al
    Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia, 2000-2016.
    Br J Haematol. 2020 Feb 23. doi: 10.1111/bjh.16492.
    PubMed     Abstract available

  415. MONDELAERS V, Ferster A, Uyttebroeck A, Brichard B, et al
    Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Br J Haematol. 2020 Feb 14. doi: 10.1111/bjh.16495.
    PubMed     Abstract available

  416. MATSUO T, Ooi J, Tashiro H, Saito S, et al
    A major break of cord blood bag.
    Br J Haematol. 2020;188:e42-e43.

  417. HOCKINGS C, Gohil S, Dowse R, Hoade Y, et al
    In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation.
    Br J Haematol. 2020;188:e53-e57.

  418. NILSSON MS, Hallner A, Brune M, Nilsson S, et al
    Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia.
    Br J Haematol. 2020;188:e49-e53.

  419. GURNEY M, Krawczyk J, Paz Nunez YE
    Megakaryocyte emperipolesis in B-lymphoblastic leukaemia.
    Br J Haematol. 2020;188:348.

  420. CAPITANO M, Capo-Chichi JM, Minden MD, Chang H, et al
    Mixed phenotype acute leukaemia with predominant myeloid blasts and a small subset of B/myeloid blasts shares the same mutation profile.
    Br J Haematol. 2020;188:e60-e63.

  421. BROWN P, Zugmaier G, Gore L, Tuglus CA, et al
    Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL.
    Br J Haematol. 2020;188:e36-e39.

  422. DA COSTA VEF, de Oliveira RD, Traina F, Chahud F, et al
    Co-occurrence of BCR-ABL1-positive chronic myeloid leukaemia and CALR-mutated essential thrombocythaemia.
    Br J Haematol. 2020;188:e21-e23.

  423. SHAHSWAR R, Beutel G, Klement P, Rehberg A, et al
    FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
    Br J Haematol. 2020;188:e11-e15.

  424. BARON F, Labopin M, Savani BN, Beohou E, et al
    Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT.
    Br J Haematol. 2020;188:428-437.
    PubMed     Abstract available

  425. HARA Y, Shiba N, Yamato G, Ohki K, et al
    Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup.
    Br J Haematol. 2020;188:528-539.
    PubMed     Abstract available

  426. HANSEN MC, Haferlach T, Nyvold CG
    A decade with whole exome sequencing in haematology.
    Br J Haematol. 2020;188:367-382.
    PubMed     Abstract available

    January 2020

  427. The Management of Acute Leukaemia in Adults.
    Br J Haematol. 2020;188:10-28.

  428. DEROLF A, Juliusson G, Benson L, Floisand Y, et al
    Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor.
    Br J Haematol. 2020;188:187-191.

  429. OLIAI C, Schiller G
    How to address second and therapy-related acute myelogenous leukaemia.
    Br J Haematol. 2020;188:116-128.
    PubMed     Abstract available

  430. CHARROT S, Armes H, Rio-Machin A, Fitzgibbon J, et al
    AML through the prism of molecular genetics.
    Br J Haematol. 2020;188:49-62.
    PubMed     Abstract available

  431. HILLS RK
    Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.
    Br J Haematol. 2020;188:29-35.
    PubMed     Abstract available

  432. PAUL S, Rausch CR, Jabbour EJ
    The face of remission induction.
    Br J Haematol. 2020;188:101-115.
    PubMed     Abstract available

  433. BURNETT AK, Hills RK, Russell N
    Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?
    Br J Haematol. 2020;188:86-100.

  434. HOKLAND P
    AML - a signature disease in haematology.
    Br J Haematol. 2020;188:7.

  435. LOKE J, Malladi R, Moss P, Craddock C, et al
    The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience.
    Br J Haematol. 2020;188:129-146.
    PubMed     Abstract available

  436. MO X, Chen H
    Acute promyelocytic leukaemia with myeloperoxidase-negative rectangular inclusions.
    Br J Haematol. 2020;188:8.

  437. HAFERLACH T, Schmidts I
    The power and potential of integrated diagnostics in acute myeloid leukaemia.
    Br J Haematol. 2020;188:36-48.
    PubMed     Abstract available

  438. GARCIA SPEZZA E, Brethon B, Petit A, Mazingue F, et al
    Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.
    Br J Haematol. 2020;188:170-173.

  439. GHOSH A, Barba P, Perales MA
    Checkpoint inhibitors in AML: are we there yet?
    Br J Haematol. 2020;188:159-167.
    PubMed     Abstract available

  440. JONES L, McCarthy P, Bond J
    Epigenetics of paediatric acute myeloid leukaemia.
    Br J Haematol. 2020;188:63-76.
    PubMed     Abstract available

  441. GHANNAM J, Dillon LW, Hourigan CS
    Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.
    Br J Haematol. 2020;188:77-85.
    PubMed     Abstract available

  442. WANG T, Wang Z, Zhang L, Wen L, et al
    Identification of a novel TFG-FGFR1 fusion gene in an acute myeloid leukaemia patient with t(3;8)(q12;p11).
    Br J Haematol. 2020;188:177-181.

    Acute myeloid leukaemia and the immune system: implications for immunotherapy.
    Br J Haematol. 2020;188:147-158.
    PubMed     Abstract available

  444. PIANIGIANI G, Betti C, Bigerna B, Rossi R, et al
    PU.1 subcellular localization in acute myeloid leukaemia with mutated NPM1.
    Br J Haematol. 2020;188:184-187.

  445. JIANG G, Atenafu EG, Capo-Chichi JM, Minden MD, et al
    Prognostic relevance of CD123 expression in adult AML with normal karyotype.
    Br J Haematol. 2020;188:181-184.

  446. ESPARZA S, Muluneh B, Galeotti J, Matson M, et al
    Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia.
    Br J Haematol. 2020;188:173-177.

  447. YIN J, Zhu S, Luo Y, Lin Z, et al
    Acute myeloid leukaemia with Auer rods within pseudo-Chediak-Higashi granules.
    Br J Haematol. 2020;188:9.

  448. KATAGIRI S, Gotoh A, Ohyashiki K
    Very late relapse with rapid BCR-ABL1 elevation after more than seven years of treatment-free remission with undetectable molecular residual disease in chronic myeloid leukaemia.
    Br J Haematol. 2020;188:332-334.

  449. RAFEI H, Kantarjian HM, Jabbour EJ
    Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
    Br J Haematol. 2020;188:207-223.
    PubMed     Abstract available

    November 2019
  450. ROSADAS C, Puccioni-Sohler M, Oliveira ACP, Casseb J, et al
    Adult T-cell leukaemia/lymphoma in Brazil: A rare disease or rarely diagnosed?
    Br J Haematol. 2019 Nov 19. doi: 10.1111/bjh.16318.

    October 2019
  451. NYLAND SB, Feith DJ, Poss M, Olson TL, et al
    Retroviral sero-reactivity in LGL leukaemia patients and family members.
    Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16223.
    PubMed     Abstract available

    July 2019
  452. FERRETTI A, Baldacci E, Miulli E, Canichella M, et al
    Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
    Br J Haematol. 2019 Jul 31. doi: 10.1111/bjh.16114.

  453. DOMINGUEZ-PINILLA N, Martinez-Zamorano E, Campos-Martin Y, Algara Plana P, et al
    Paediatric-type nodal follicular lymphoma in a child diagnosed with chronic myeloid leukaemia.
    Br J Haematol. 2019 Jul 8. doi: 10.1111/bjh.16089.

    June 2019
  454. SAKAMOTO K, Shiba N, Deguchi T, Kiyokawa N, et al
    Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Jun 27. doi: 10.1111/bjh.16080.
    PubMed     Abstract available

    May 2019
  455. KHOGEER H, Rahman H, Jain N, Angelova EA, et al
    Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
    Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15960.
    PubMed     Abstract available

  456. TOYODA K, Tsukasaki K, Machida R, Kadota T, et al
    Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801.
    Br J Haematol. 2019 May 16. doi: 10.1111/bjh.15950.
    PubMed     Abstract available

    February 2019
  457. KHASHAB T, Hagemeister F, Romaguera JE, Fanale MA, et al
    Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 28. doi: 10.1111/bjh.15814.
    PubMed     Abstract available

  458. BURKHARDT B, Hermiston ML
    Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
    Br J Haematol. 2019 Feb 27. doi: 10.1111/bjh.15793.
    PubMed     Abstract available

  459. MIYAMURA T, Moritake H, Nakayama H, Tanaka S, et al
    Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Feb 19. doi: 10.1111/bjh.15799.
    PubMed     Abstract available

  460. O'REILLY MA, Govender D, Kirkwood AA, Vora A, et al
    The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study.
    Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15798.

    January 2019
  461. BATALLER A, Combalia A, Garcia-Herrera A, Estrach T, et al
    Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2019 Jan 6. doi: 10.1111/bjh.15744.

    August 2018
  462. SU C, Bai HX, Xiao R
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some of the apparent ethnic dispa
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15526.

  463. LO BELLO G, Naresh KN
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some apparent ethnic disparities.
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15527.

    July 2018
  464. AILAWADHI S, Dholaria BR, Khurana S, Sher T, et al
    Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15458.

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.